Related references
Note: Only part of the references are listed.Growth hormone response during oral glucose tolerance test:: The impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index
Ayman M. Arafat et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Mortality in acromegaly: A meta analysis
O. M. Dekkers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Radiation therapy in acromegaly
Helen A. Shih et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2008)
A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
Moises Mercado et al.
CLINICAL ENDOCRINOLOGY (2007)
Effect of transsphenoidal surgery on sleep apnoea in acromegaly
Lisa Sze et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Valvular heart disease and the use of dopamine agonists for Parkinson's disease
Renzo Zanettini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant
Craig Parkinson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study
I. Schreiber et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Medical progress: Acromegaly
Shlomo Melmed
NEW ENGLAND JOURNAL OF MEDICINE (2006)
High prevalence of pituitary adenomas: A cross-sectional study in the province of Liege, Belgium
Adrian F. Daly et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Gamma knife radiosurgery for acromegaly -: long-term experience
J Jezková et al.
CLINICAL ENDOCRINOLOGY (2006)
Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation
AA van der Klaauw et al.
GROWTH HORMONE & IGF RESEARCH (2006)
Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage
R Cozzi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on lGF-I levels, tumor mass, hypertension and glucose tolerance
A Colao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: Effects on cardiovascular risk factors
CL Ronchi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly
A Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Transsphenoidal microsurgery for newly diagnosed acromegaly: A personal view after more than 1,000 operations
Dieter K. Luedecke et al.
NEUROENDOCRINOLOGY (2006)
Consensus statement: medical management of acromegaly
S Melmed et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Outcome of gamma knife radiosurgery in 82 patients with acromegaly:: Correlation with initial hypersecretion
F Castinetti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Long-acting somatostatin analog therapy of acromegaly: A meta- analysis
PU Freda et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
CLINICAL REVIEW: A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly
S Melmed et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Diagnosis and treatment of acromegaly
L Katznelson
GROWTH HORMONE & IGF RESEARCH (2005)
Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy
P Jaquet et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly
J Feenstra et al.
LANCET (2005)
Risk of colorectal neoplasm in patients with acromegaly and its relationship with serum growth hormone levels
Y Matano et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'
P Nomikos et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Colonoscopic screening and follow-up in patients with acromegaly: A multicenter study in Italy
M Terzolo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients
J van der Hoek et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Factors influencing mortality in acromegaly
IM Holdaway et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Significance of abnormal nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels
PU Freda et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
The heart: an end-organ of GH action
A Colao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status
R Cozzi et al.
CLINICAL ENDOCRINOLOGY (2004)
The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion
RD Murray et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espahol de Acromegalia, REA)
A Mestrón et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
High prevalence of cardiac valve disease in acromegaly: An observational, analytical, case-control study
A Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Acromegaly consensus: The next steps
A Giustina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells
A Saveanu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Primary medical therapy for acromegaly: An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size
JS Bevan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
AJ van der Lely et al.
LANCET (2001)
Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels
NR Biermasz et al.
CLINICAL ENDOCRINOLOGY (2000)
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
PJ Trainer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
